Cholangiocarcinoma, a cancer arising from the bile ducts, spreads through multiple routes and tends to be diagnosed late, which makes metastasis a central challenge in managing the disease. The liver is the most common destination for distant spread, but lung, peritoneum, and bone are also frequent targets, with the pattern varying depending on whether the tumor starts inside or outside the liver. Treatment has evolved considerably in recent years, with immunotherapy combinations and molecularly targeted drugs offering meaningful survival gains for the first time, even in patients with advanced or metastatic disease.
How Cholangiocarcinoma Spreads
Cholangiocarcinoma does not spread through a single mechanism. Tumors arising in the extrahepatic bile ducts can metastasize by direct invasion into surrounding organs, seeding along the peritoneal lining, entering the bloodstream, traveling through lymphatic channels, or creeping along nearby nerves. That last route, perineural invasion, is reported in roughly 40% to nearly 90% of patients with extrahepatic disease, making it one of the most common and clinically important pathways. It is strongly linked to recurrence after surgery and poorer outcomes.1Journal of Gastrointestinal Surgery. Perineural Invasion in Extrahepatic Cholangiocarcinoma: Prognostic Impact and Treatment Strategies
Perineural invasion deserves special attention because nerves provide a physical scaffold that tumor cells can follow for long distances beyond the visible edges of the primary mass. This is a major reason why surgical margins that look clear on imaging sometimes harbor microscopic disease, contributing to the high recurrence rates seen even after apparently curative operations.2PubMed Central. Current research in perineural invasion of cholangiocarcinoma
Where Metastases Tend to Appear
The pattern of distant spread depends on where the tumor originates. For extrahepatic bile duct cancers, the liver is the dominant site, receiving metastases in about half of all cases. Distant lymph nodes, lung, bone, and brain follow in decreasing order, with brain metastasis being quite rare.3PubMed Central. Pattern of distant metastases in primary extrahepatic bile‐duct cancer: A SEER‐based study
Intrahepatic cholangiocarcinoma tells a somewhat different story. In a study of 370 patients, about half developed distant metastases either at diagnosis or during follow-up. The lung was the most frequently involved site, followed by the peritoneum and then bone.4PubMed Central. Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients Compared to hepatocellular carcinoma (the other main type of primary liver cancer), intrahepatic cholangiocarcinoma shows somewhat lower rates of lung and bone metastasis but a similar rarity of brain involvement.5PubMed Central. Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study
Knowing these patterns matters practically. Surveillance imaging after treatment can be tailored to focus on the likeliest sites of recurrence. For example, cross-sectional imaging of the chest and abdomen is standard, while routine brain imaging generally is not warranted given the extreme rarity of brain metastases from bile duct cancers.
What Drives the Spread at a Cellular Level
For a cholangiocarcinoma cell to leave the primary tumor and establish itself elsewhere, it needs to acquire the ability to move and invade surrounding tissue. This happens through a process in which cells switch from a fixed, tightly connected state to a more mobile, loosely attached state. Researchers call this epithelial-mesenchymal transition, and it has become one of the most studied phenomena in cholangiocarcinoma biology.6Journal of Hepatology. Cholangiocarcinoma: Epithelial-mesenchymal transition, cell plasticity, and stroma The transition is reversible, meaning cells can revert to their original state once they land at a distant site and begin growing a new tumor.
One of the key chemical signals driving this switch is a growth factor called TGF-beta1, which activates a protein called Snail inside the cell’s nucleus. In laboratory and animal models, TGF-beta1 exposure caused cholangiocarcinoma cells to lose markers of their original identity and gain markers of mobile, invasive cells. In mice, TGF-beta1 worsened the spread of tumor cells throughout the abdominal cavity.7PubMed Central. Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma
The Role of the Tumor’s Surroundings
Cholangiocarcinoma is notorious for generating a dense, fibrous tissue reaction around itself, sometimes called a desmoplastic stroma. This is not inert scaffolding. Within this fibrous shell, specialized cells called myofibroblasts engage in a back-and-forth chemical conversation with the tumor. When cholangiocarcinoma cells were co-transplanted with human liver myofibroblasts in experimental models, tumor growth and metastatic spread both increased, driven by signaling through the epidermal growth factor receptor.8Journal of Hepatology. Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Interestingly, the stroma’s relationship with the tumor is not straightforward. A study of intrahepatic cholangiocarcinoma found that tumors with a higher proportion of stroma relative to tumor cells actually had lower rates of vascular invasion and better differentiation. Patients in this group trended toward better disease-free survival. In other words, a large amount of dense, organized stroma may actually act as a physical barrier against spread, while a stroma packed with highly activated fibroblasts appears more dangerous.9PubMed. Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma This paradox, where the tumor’s own support tissue can either help or hinder it depending on its composition, is an active area of research.
Detecting Spread
Standard imaging with CT and MRI remains the backbone of initial staging. These modalities can identify the primary tumor, assess for liver involvement, and detect enlarged lymph nodes or peritoneal deposits. However, they can miss small metastases, particularly in the peritoneum or bones.
PET scanning, which detects areas of heightened metabolic activity, adds a significant layer of sensitivity. One review found that PET-CT achieved a perfect detection rate for distant metastases, outperforming conventional imaging and changing the management plan in a meaningful proportion of cases.10PubMed Central. Positron emission tomography (PET) for cholangiocarcinoma That said, PET has well-known blind spots: some slow-growing or mucin-producing tumors do not light up brightly, and inflammatory conditions can produce false positives. It is most useful for detecting unsuspected distant disease before a patient is committed to major surgery.
Blood-based tumor markers offer additional clues. CA 19-9 is the most widely used marker in clinical practice for bile duct cancers. Its levels climb as the disease advances. Patients with CA 19-9 levels above 1,000 U/mL or CEA levels above about 14 ng/mL before surgery had significantly worse resectability rates and survival.11PubMed Central. Tumor markers as a diagnostic key for hilar cholangiocarcinoma However, CA 19-9 is not specific to cholangiocarcinoma. It can be elevated by simple bile duct blockage, infection, or other gastrointestinal cancers, so it is best used alongside imaging rather than in isolation.
Liquid Biopsy and Newer Biomarkers
An emerging alternative to traditional tissue biopsies involves testing blood for tumor-derived DNA fragments, known as circulating tumor DNA. These fragments carry the same genetic mutations as the primary cancer, such as IDH1/2 mutations or FGFR2 gene fusions, and can reflect epigenetic changes like abnormal methylation patterns.12PubMed Central. Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives The appeal is straightforward: a blood draw is far less invasive than a liver biopsy, and it can be repeated over time to track how the tumor is responding to treatment or whether it is developing resistance to a targeted drug.13PubMed Central. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
Liquid biopsy is already being used clinically in some settings to guide the selection of targeted therapies, and it plays a growing role in detecting resistance mutations (more on that below). Its role in early detection and screening remains largely investigational, but the technology is advancing rapidly.
How Staging Shapes the Outlook
Staging systems group patients by how far the cancer has progressed, and in cholangiocarcinoma the survival differences between stages are stark. For intrahepatic disease, data from both multi-institutional registries and the national SEER database show a clear stepwise decline in survival with each advancing stage. Patients with early-stage disease had a median survival approaching six years or more, while those with stage IV disease had a median of about 14 to 16 months.14HPB (Oxford) / ScienceDirect. Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma That gap underscores why detecting spread early, before it reaches distant organs, matters so much for treatment planning.
Systemic Therapy for Advanced Disease
For decades, the combination of gemcitabine and cisplatin was the only systemic regimen with strong evidence behind it for advanced biliary tract cancers. That changed with the addition of the immune checkpoint inhibitor durvalumab. In a large randomized trial, adding durvalumab to standard chemotherapy reduced the risk of death by about 20% compared to chemotherapy alone. The two-year survival rate roughly doubled, from about 10% with chemotherapy alone to about 25% with the combination.15PubMed. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer A phase 2 study exploring similar immunotherapy-chemotherapy combinations achieved even higher response rates, with roughly two-thirds of patients experiencing tumor shrinkage.16The Lancet Gastroenterology & Hepatology. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in untreated advanced biliary tract cancer
Gemcitabine-cisplatin plus durvalumab has become the standard first-line treatment for patients with unresectable or metastatic cholangiocarcinoma who are well enough to receive combination chemotherapy. It is not a cure, but it represents a genuine improvement over what was available just a few years ago.
Targeted Therapies Based on Tumor Genetics
A significant subset of cholangiocarcinomas carry genetic alterations that can be directly targeted with newer drugs. Two of the most actionable are FGFR2 fusions and IDH1 mutations, both found predominantly in intrahepatic tumors.
Pemigatinib, a selective inhibitor of FGFR receptors, gained regulatory approval in the United States for patients whose intrahepatic cholangiocarcinoma harbors FGFR2 fusions or rearrangements.17Cancer Discovery. Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib In real-world use across French and Italian centers, about 46% of patients responded, with a median progression-free survival of nearly nine months and a median overall survival of about 17 months.18PubMed. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements Those numbers are notable for patients who have already progressed through at least one prior line of chemotherapy.
For tumors carrying IDH1 mutations, ivosidenib has shown clinical benefit. A randomized phase 3 trial in chemotherapy-refractory patients found that ivosidenib significantly improved progression-free survival compared to placebo.19PubMed Central. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study The overall survival benefit was harder to pin down in the original analysis because many patients assigned to placebo crossed over to ivosidenib after progression, which diluted the survival difference. After statistically adjusting for crossover, the median survival with placebo dropped to about 5 months versus about 10 months with ivosidenib.20JAMA Oncology. Final Overall Survival Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial Real-world data have been consistent, with one multicenter study reporting a median overall survival of about 11.5 months on ivosidenib and a significantly better outcome compared to standard chemotherapy in a similar patient group.21PubMed Central. Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study
HER2 overexpression is another targetable alteration, though it is less common in cholangiocarcinoma than in breast or gastric cancers. Early clinical trial data for zanidatamab, a bispecific antibody directed against HER2, showed a response rate of about 41% in HER2-positive bile duct cancers with durable responses. Antibody-drug conjugates targeting HER2, already approved in other cancers, have also shown disease control rates of roughly 75% to 82% in early cholangiocarcinoma studies.22PubMed Central. Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma
When Targeted Drugs Stop Working
One of the frustrations of FGFR-targeted therapy is that resistance develops in the majority of patients who initially respond. In a large analysis, about 60% of patients who progressed on FGFR inhibitors had acquired new mutations in the FGFR2 gene itself, concentrated at two critical spots in the protein’s structure. Most of these patients developed multiple resistance mutations simultaneously, a phenomenon called polyclonal resistance.23PubMed Central. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Subsequent research has shed light on why this happens. Patients who initially benefited from FGFR inhibitors were far more likely to develop these kinase domain mutations than patients who never responded, consistent with the idea that the drug successfully suppresses the dominant clone while selecting for resistant subpopulations. Laboratory testing showed that newer, broader FGFR inhibitors could overcome many individual resistance mutations, but the clinically achievable drug concentrations may not be high enough to suppress all of them simultaneously, especially when multiple resistant clones emerge at once.24PubMed. A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma This is one reason liquid biopsy tracking of circulating tumor DNA is so valuable in this setting: it can detect the emergence of resistance mutations months before imaging shows tumor growth, potentially allowing for earlier strategy changes.
Liver-Directed and Surgical Approaches
For tumors confined to or predominantly within the liver, locoregional treatments can complement or sometimes substitute for systemic drugs. These include hepatic arterial infusion of chemotherapy directly into the liver’s blood supply, transarterial chemoembolization, and radioembolization with yttrium-90 microspheres. A comparative analysis found that hepatic arterial infusion achieved the highest median survival (nearly 23 months) and the best response rates (about 57%) among these approaches, though it is available at fewer centers and requires specialized expertise. Radioembolization and chemoembolization showed more modest but still meaningful activity.25PubMed. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma Most of the existing data come from single-arm studies without a control group, so isolating the true contribution of these treatments beyond systemic therapy remains difficult.26PubMed Central. Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma
Liver transplantation, once considered inappropriate for cholangiocarcinoma, has re-entered the conversation for specific patient groups. For perihilar tumors, select centers use a protocol of neoadjuvant chemoradiation followed by transplantation. Among patients who entered this protocol, about 62% ultimately reached transplant, with disease progression or metastases found at staging surgery being the main reasons others did not. Those who did undergo transplant had five-year survival rates near 68% and ten-year rates around 60%.27PubMed Central. Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances For intrahepatic tumors, transplant is far more experimental. An intention-to-treat study using chemotherapy and radioembolization to downstage unresectable intrahepatic tumors resulted in four of thirteen patients successfully reaching transplant, all of whom were alive and disease-free at last follow-up.28Transplant International. Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study Standard hepatectomy remains the primary surgical treatment for resectable intrahepatic disease, but transplant may offer an option for carefully selected patients with unresectable tumors who respond well to preoperative treatment.29PubMed. Contemporary trends and outcomes after liver transplantation and resection for intrahepatic cholangiocarcinoma
Managing Symptoms When the Bile Duct Is Blocked
Many patients with cholangiocarcinoma develop obstruction of the bile duct, which causes jaundice, itching, and risk of life-threatening biliary infection. Relieving this blockage is often the most urgent clinical priority, regardless of whether the cancer is curable. Endoscopic placement of a stent through the bile duct opening is considered the gold standard approach, achieving successful drainage in about 90% to 95% of cases and providing significant quality-of-life improvement.30PubMed Central. Endoscopic palliation of malignant biliary obstruction When endoscopic access is not feasible, interventional radiologists can place drainage catheters or stents through the skin.31PubMed Central. Management of Malignant Biliary Obstruction
Stent selection matters for durability. Standard metal stents eventually become blocked again as tumor grows through or around them. Radiation-emitting metallic stents, which deliver low-dose radiation directly to the bile duct wall, have shown significantly longer patency and better survival than conventional metal stents in patients with advanced hilar cholangiocarcinoma. In one study, median stent patency was roughly 385 days with radiation-emitting stents versus 142 days with standard ones, and median survival more than doubled.32ESMO Open. Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma
Investigational Treatments on the Horizon
Beyond the drugs already in clinical use, several new strategies are being explored. Antibody-drug conjugates, which deliver potent chemotherapy payloads directly to cells bearing a specific surface marker, are in preclinical and early clinical testing. Conjugates targeting HER2 and other surface proteins like MUC1 and glypican-1 have shown anti-cancer activity against cholangiocarcinoma cells in the laboratory.33PubMed Central. Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives
Cell-based therapies are also entering early trials. One phase 1/2 study is testing an off-the-shelf product composed of natural killer cells engineered to recognize both HER2 and CEA, two proteins commonly found on biliary tract cancer cells, in patients with unresectable or metastatic cholangiocarcinoma who have exhausted standard treatments.34TrialX. Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer These approaches remain experimental, but they signal a shift toward more personalized, immune-based treatment options for a cancer that has historically had very few.
Geographic Risk and the Liver Fluke Connection
Cholangiocarcinoma incidence varies dramatically around the world, and the reasons are directly tied to metastasis patterns because late presentation in high-incidence regions means more patients arrive with advanced or metastatic disease. In parts of Thailand and Southeast Asia, cholangiocarcinoma rates are far higher than anywhere else, driven largely by chronic infection with the liver fluke Opisthorchis viverrini, a parasite acquired by eating raw or undercooked freshwater fish. The fluke lodges in the bile ducts and triggers chronic inflammation, oxidative DNA damage, and eventually malignant transformation of the duct lining.35PubMed Central. Cholangiocarcinoma: lessons from Thailand In Western countries, most cholangiocarcinoma cases arise without a clear parasitic cause, linked instead to conditions like primary sclerosing cholangitis, chronic hepatitis, or increasingly no identifiable risk factor at all.
A small study from northeastern Thailand explored whether medicinal cannabis could improve quality of life for patients with advanced cholangiocarcinoma receiving palliative care. Over four months, patients in the cannabis group had consistently better performance status and quality-of-life scores, along with improved symptom control, compared to those receiving standard palliative care alone.36F1000Research. Comparison of effects of medicinal cannabis or standard palliative care on quality of life of patients with cholangiocarcinoma in Northeast Thailand These findings are preliminary and come from a single center in a high-incidence region, but they highlight the unmet need for better supportive care options in a disease that remains difficult to cure.